Discover how AI-based assays offer a promising approach to tailor treatment for high-risk non-muscle-invasive bladder cancer.

Updated results from the NIAGARA trial further support perioperative durvalumab and neoadjuvant chemotherapy as a potential new treatment for patients with muscle-invasive bladder cancer, according to ...

Amid a rapidly evolving landscape in the treatment of muscle-invasive bladder cancer (MIBC), new findings presented at the 2025 ASCO Genitourinary Cancers Symposium in San Francisco, California, ...

An expert discusses how adjuvant therapy options for high-risk muscle-invasive bladder cancer (MIBC); ypT2-ypT4a or N+) ...

An expert discusses how patients with muscle-invasive urothelial carcinoma (MIUC) undergoing radical cystectomy face a ...

Avoiding surgery for rectal cancer, Sarah Rack of Memphis traveled to Houston for treatment every three weeks for 18 months.

Radical cystectomy (RC) is the guideline-recommended gold standard of curative treatment for muscle-invasive bladder cancer (MIBC). Trimodality therapy (TMT) has recently emerged as a viable ...

Patients with muscle-invasive bladder cancer (MIBC) who develop a recurrence after radical cystectomy (RC) have poor outcomes. This study aims to evaluate the safety and efficacy of adjuvant ...

Preferred treatment regimens for rare genitourinary (GU) malignancies. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium. This abstract does not include a full text ...

Inclusion of patients with reduced performance status (ECOG 2 or higher) in FDA registrational trials for urothelial cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers ...

The standard of care for localized MIBC is radical cystectomy, the removal of the entire bladder. While it is typically effective, it can have lasting impacts on a patient's life, explained Garcia ...